Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer Patients
Christopher G. Willett, Gregory Y. Lauwers(Moffitt Cancer Center), Dan G. Duda(Harvard University), Kenneth S. Cohen(University of Chicago), Yves Boucher(Harvard University), Paul C. Shellito(Harvard University), Alan J. Fischman(Shriners Hospitals for Children), Sanjeeva P. Kalva(Massachusetts General Hospital), Dushyant V. Sahani(Brigham and Women's Hospital), David P. Ryan(East Carolina University), Mari Mino–Kenudson(Massachusetts General Hospital), Sergey V. Kozin(Sechenov University), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), David T. Scadden(Harvard University), Daniel C. Chung(Massachusetts General Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Ricky T. Tong(Harvard University), Lance L. Munn(Massachusetts General Hospital), Lucine Petit(Harvard University), Emmanuelle di Tomaso(Bayer (United States))
Cited by 419
Related Papers
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k